FindTrial
Sign In

A study to understand how children with brain or nerve swelling get sick and recover

Clinical profile and outcomes of children with acquired demyelinating syndromes - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/096738
Enrollment
30
Registered
2025-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G378- Other specified demyelinating diseases of central nervous system

Interventions

Intervention1: Nil: Nil

Sponsors

Department of paediatrics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children aged 1 month to 18 years fulfilling diagnostic criteria for ADSs (ADEM, MS, NMOSD, GBS, transverse myelitis)

Exclusion criteria

Exclusion criteria: Children with genetic, metabolic, or toxic encephalopathies Head trauma Pre-existing neurological malformations

Design outcomes

Primary

MeasureTime frame
Etiology, hospital & ICU stay duration, treatment modalities usedTimepoint: At baseline, 7 days—

Secondary

MeasureTime frame
Survival/death, focal neurological deficit, vision/hearing impairment, motor sequelaeTimepoint: 3 months after discharge.—

Countries

India

Contacts

Public ContactShekhar Dixit

Department of Pediatrics Kasturba Medical College Manipal

karen.moras@manipal.edu9980782769

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026